POLE EC pilot study: Identification of neo-antigen specific immunity in POLE-mutant endometrial cancer

POLE EC pilot study: Identification of neo-antigen specific immunity in POLE-mutant endometrial cancer - POLE-EC001

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44597

Enrollment

Registered

2017-12-14

Start date

2018-04-20

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the womb uterine cancer

Interventions

Endometrial cancer

Immunity

Neo-antigens

T-cells

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Women with POLE mutated endometrial cancer - Adequate venous access for blood collection - 18 years of age or older - Availability of tumour digest in biobank - Informed consent

Exclusion criteria

Exclusion criteria: - Previous or concurrent malignancy - Current treatment with immunosuppressive therapy

Design outcomes

Primary

Measure	Time frame
Detection of neo-antigen specific cellular immunity in POLE-mutant endometrial cancer patients.	—

Secondary

Measure	Time frame
None	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)